EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Scorecard

Which seven gates must pass before commercial ranking?

Dose Diligence research deskSection 09 · Page 4 of 15Last updated 17 Nov 2026

Every gate needs an accountable reviewer and dated evidence. PASS means the designated specialist accepts the evidence for the defined scope—not that the research desk certifies legality or safety.

  • PASS: required evidence reviewed and accepted for the stated arrangement.
  • HOLD: material evidence is missing, stale, contradictory or awaiting specialist interpretation.
  • FAIL: the reviewer identifies an unacceptable condition in the proposed arrangement.

A HOLD is not an allegation of wrongdoing. A FAIL applies to the assessed arrangement and may be reconsidered after a documented remedy. Neither receives a commercial ranking while unresolved.

GateEvidence required to pass under this methodologyHOLD or FAIL triggersApproval owner
G1. Counterparty, facility and destination permissionsMatch legal names, addresses and relevant licence identifiers; verify applicable home-state and destination-state permissions; identify subcontracted dispensing locations.A trading name substitutes for the actual pharmacy; required permissions cannot be verified; an undisclosed facility performs fulfilment.Compliance and counsel
G2. Product and supply-route eligibilityIdentify approved or compounded status, exact preparation, intended use and statutory pathway. For proposed compounding, obtain preparation-specific clinical and legal review.Reliance only on patient-specific prescribing, an added ingredient, FDA registration, or a historic shortage.Medical director and counsel
G3. Provenance and traceabilityIdentify the source and distribution chain; obtain relevant transaction records and an allocation of applicable DSCSA responsibilities; test lot identification and quarantine procedures.Unexplained intermediaries, mismatched labels or invoices, or inability to identify affected supply.Pharmacy/quality lead and compliance
G4. Quality, storage and recall readinessReview facility-specific inspection and remediation records, applicable quality documentation, product-specific storage controls, excursion handling and recall procedures. For eligible compounded preparations, request formulation-relevant testing and dating support.Material quality concerns remain unresolved; the supplier will not provide sufficient assurance; storage or recall responsibilities are unassigned.Qualified quality reviewer and medical director
G5. Medication-use safety and clinical independenceApprove label examples, concentration/device instructions, pharmacist access, complaint and adverse-event escalation, and product-change controls. Prescribing decisions remain with clinicians.Instructions cannot be reconciled; commercial staff determine treatment changes; clinical escalation has no accountable owner.Medical director and pharmacy lead
G6. Privacy and securityMap data flows and legal roles; assess access controls, subcontractors, incident handling and required agreements.Unapproved data uses, material security gaps, or missing agreements where required.Privacy counsel and security lead
G7. Financial-arrangement complianceReview fees, rebates, ownership links, marketing support and referral-related remuneration under the applicable federal and state framework.The commercial model depends on payments counsel cannot approve or undisclosed financial interests.Counsel and CFO

What legal distinctions must the gate reviewers preserve?

503A and 503B are different pathways. FDA explains that patient-specific prescriptions are among the conditions of section 503A, while qualifying 503B outsourcing arrangements may supply non-patient-specific office stock and remain subject to current good manufacturing practice requirements. The ability to supply office stock does not establish eligibility for a particular GLP-1 preparation. (fda.gov)

FDA’s 2026 clarification also explains that a documented prescriber determination of a significant difference for an identified patient matters to the 503A essentially-copy analysis. It specifically addresses circumstances in which adding vitamin B12 can still result in an essentially-copy product. Neither a prescription nor an additive is automatic clearance. (fda.gov)

For distributors, FDA states that appropriate licensing and annual reporting are needed for authorised-trading-partner status, but appearing in its reporting database is not itself proof of licensing, approval or compliance. Verify the underlying records. (fda.gov)

For state coverage, California provides a useful—not nationwide—example: nonresident dispensing requires relevant home-state and California licensing, while shipping sterile compounded products adds a separate sterile-compounding licence requirement. (pharmacy.ca.gov)

How should quality evidence be interpreted?

Review the facility and the finding, not merely whether a document exists. FDA’s outsourcing register identifies facilities, inspections and follow-up actions; the version retrieved displayed a November 6, 2026 update date. Match the actual supplying location and review associated inspection, recall and enforcement material. (fda.gov)

A Form FDA 483 records inspection observations; FDA says it is not a final agency determination of a violation. Request the response, corrective actions and subsequent regulatory disposition rather than automatically passing or rejecting every facility with a 483. (fda.gov)

For outsourced sterile compounding, ASHP’s guidelines identify testing policies, batch records, stability support and inspection follow-up as relevant diligence material. Use these as document-request categories, with a qualified reviewer applying current requirements—not as proof that a particular GLP-1 preparation is eligible. (ashp.org)

FDA has documented compounded semaglutide dosing errors involving differing concentrations and confusion among milligrams, millilitres and syringe units. Require clinical review of the actual prescription, label and administration-device combination rather than a generic training leaflet. (fda.gov)

Does every pharmacy relationship require a business associate agreement?

No: determine the parties’ actual roles. HHS distinguishes business-associate services from disclosures to another healthcare provider for treatment, for which a BAA is not automatically required. A connected software or administrative service may require different treatment from the dispensing pharmacy itself. (hhs.gov)

Similarly, the federal Anti-Kickback Statute addresses knowing and willful remuneration to induce or reward business payable by federal healthcare programmes. Ask counsel to assess the actual facts and applicable state rules; do not assume that calling a payment a technology fee resolves the issue. (oig.hhs.gov)

Explore the table row by row

A working view of the research

G1. Counterparty, facility and destination permissions

Evidence required to pass under this methodology
Match legal names, addresses and relevant licence identifiers; verify applicable home-state and destination-state permissions; identify subcontracted dispensing locations.
HOLD or FAIL triggers
A trading name substitutes for the actual pharmacy; required permissions cannot be verified; an undisclosed facility performs fulfilment.
Approval owner
Compliance and counsel

Sources cited on this page

  1. fda.gov · Source 1 ↗https://www.fda.gov/drugs/human-drug-compounding/human-drug-compounding-laws
  2. fda.gov · Source 2 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  3. fda.gov · Source 3 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/annual-licensure-reporting-wholesale-drug-distributors-and-third-party-logistics-providers
  4. pharmacy.ca.gov · Source 4 ↗https://www.pharmacy.ca.gov/applicants/phy.shtml
  5. fda.gov · Source 5 ↗https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
  6. fda.gov · Source 6 ↗https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/fda-form-483-frequently-asked-questions?utm_source=openai
  7. ashp.org · Source 7 ↗https://www.ashp.org/-/media/assets/news-and-media/docs/ASHP-Guidelines-on-Outsourcing-Sterile-Compounding-Services.pdf
  8. fda.gov · Source 8 ↗https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded?utm_source=openai
  9. hhs.gov · Source 9 ↗https://www.hhs.gov/hipaa/for-professionals/privacy/guidance/business-associates/index.html
  10. oig.hhs.gov · Source 10 ↗https://www.oig.hhs.gov/compliance/physician-education/fraud-abuse-laws/
Section sources →